Literature DB >> 15299052

Perfusable tissue index as a potential marker of fibrosis in patients with idiopathic dilated cardiomyopathy.

Paul Knaapen1, Ronald Boellaard, Marco J W Götte, Pieter A Dijkmans, Linda M C van Campen, Carel C de Cock, Gert Luurtsema, Cees A Visser, Adriaan A Lammertsma, Frans C Visser.   

Abstract

UNLABELLED: A varying degree of interstitial and perivascular fibrosis is a common finding in idiopathic dilated cardiomyopathy (DCM). The perfusable tissue index (PTI), obtained with PET, is a noninvasive tool for assessing myocardial fibrosis on a regional level. Measurements of the PTI in DCM, however, have not been performed yet. This study was undertaken to test the hypothesis that the PTI is reduced in patients with DCM.
METHODS: Fifteen patients with an advanced stage of DCM (New York Heart Association class III or IV and left ventricular ejection fraction [LVEF] < 35%) and 11 healthy control subjects were studied. PET was performed using H(2)(15)O and C(15)O to obtain the perfusable tissue fraction (PTF) and the anatomic tissue fraction (ATF), respectively.
RESULTS: The PTI (=PTF/ATF) was reduced in DCM compared with control subjects (0.91 +/- 0.12 vs. 1.12 +/- 0.10; P < 0.01). Heterogeneity of the PTI, expressed as the coefficient of variation, was increased in DCM versus that of healthy control subjects (0.18 +/- 0.07 vs. 0.13 +/- 0.06; P < 0.05). There was no correlation between the PTI and echocardiographically derived LVEF in both groups.
CONCLUSION: The PTI was reduced in patients with an advanced stage of DCM. Interstitial and perivascular fibrosis may be responsible for this reduction. Furthermore, the degree of the PTI reduction was variable in DCM patients, both on a regional level and between patients. Noninvasive assessment of fibrosis with the PTI offers the opportunity to evaluate the effects of fibrosis on regional myocardial function, correlate fibrosis with prognosis, and monitor pharmaceutical intervention.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15299052

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  21 in total

1.  Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study.

Authors:  Roni Nielsen; Anders Jorsal; Peter Iversen; Lars Poulsen Tolbod; Kirsten Bouchelouche; Jens Sørensen; Hendrik Johannes Harms; Allan Flyvbjerg; Lise Tarnow; Caroline Kistorp; Ida Gustafsson; Hans Erik Bøtker; Henrik Wiggers
Journal:  J Nucl Cardiol       Date:  2017-08-02       Impact factor: 5.952

2.  Assessment of endothelial function and myocardial flow reserve using (15)O-water PET without attenuation correction.

Authors:  Stéphane Tuffier; Damien Legallois; Annette Belin; Michael Joubert; Alban Bailliez; Michel Redonnet; Denis Agostini; Alain Manrique
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-18       Impact factor: 9.236

3.  99 mTc-MIBI washout as a complementary factor in the evaluation of idiopathic dilated cardiomyopathy (IDCM) using myocardial perfusion imaging.

Authors:  Mohammad Kazem Shiroodi; Babak Shafiei; Nastaran Baharfard; Mohammad Esmail Gheidari; Babak Nazari; Elaheh Pirayesh; Ali Kiasat; Samaneh Hoseinzadeh; Abolghassem Hashemi; Mohammad Ali Akbarzadeh; Hamid Javadi; Iraj Nabipour; Majid Assadi
Journal:  Int J Cardiovasc Imaging       Date:  2010-12-28       Impact factor: 2.357

4.  Regional heterogeneity of resting perfusion in hypertrophic cardiomyopathy is related to delayed contrast enhancement but not to systolic function: a PET and MRI study.

Authors:  Paul Knaapen; Willem G van Dockum; Marco J W Götte; Kimiko A Broeze; Joost P A Kuijer; Jaco J M Zwanenburg; J Tim Marcus; Wouter E M Kok; Albert C van Rossum; Adriaan A Lammertsma; Frans C Visser
Journal:  J Nucl Cardiol       Date:  2006-09       Impact factor: 5.952

5.  Effects of patient movement on measurements of myocardial blood flow and viability in resting ¹⁵O-water PET studies.

Authors:  Kazuhiro Koshino; Hiroshi Watabe; Junichiro Enmi; Yoshiyuki Hirano; Tsutomu Zeniya; Shinji Hasegawa; Takuya Hayashi; Shigeru Miyagawa; Yoshiki Sawa; Jun Hatazawa; Hidehiro Iida
Journal:  J Nucl Cardiol       Date:  2012-06       Impact factor: 5.952

6.  Impact of scar on water-perfusable tissue index in chronic ischemic heart disease: Evaluation with PET and contrast-enhanced MRI.

Authors:  Paul Knaapen; Olga Bondarenko; Aernout M Beek; Marco J W Götte; Ronald Boellaard; Arno P van der Weerdt; Cees A Visser; Albert C van Rossum; Adriaan A Lammertsma; Frans C Visser
Journal:  Mol Imaging Biol       Date:  2006 Jul-Aug       Impact factor: 3.488

Review 7.  Radionuclide noninvasive evaluation of heart failure beyond left ventricular function assessment.

Authors:  Albert Flotats; Ignasi Carrió
Journal:  J Nucl Cardiol       Date:  2009-02-27       Impact factor: 5.952

8.  Measurement of left ventricular volumes and function with O-15-labeled carbon monoxide gated positron emission tomography: comparison with magnetic resonance imaging.

Authors:  Hadassa A Hofman; Paul Knaapen; Ronald Boellaard; Olga Bondarenko; Marco J W Götte; Willem G van Dockum; Cees A Visser; Albert C van Rossum; Adriaan A Lammertsma; Frans C Visser
Journal:  J Nucl Cardiol       Date:  2005 Nov-Dec       Impact factor: 5.952

9.  Kinetic models for analysing myocardial [(11)C]palmitate data.

Authors:  Hugo W A M de Jong; Luuk J Rijzewijk; Mark Lubberink; Rutger W van der Meer; Hildo J Lamb; Jan W A Smit; Michaëla Diamant; Adriaan A Lammertsma
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-27       Impact factor: 9.236

10.  Cardiac magnetic resonance imaging of myocardial contrast uptake and blood flow in patients affected with idiopathic or familial dilated cardiomyopathy.

Authors:  Michael Jerosch-Herold; David C Sheridan; Jessica D Kushner; Deirdre Nauman; Donna Burgess; Diana Dutton; Rami Alharethi; Duanxiang Li; Ray E Hershberger
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-07-25       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.